Literature DB >> 24982768

Technical aspects of radiation therapy for anal cancer.

Eli D Scher1, Inaya Ahmed1, Ning J Yue1, Salma K Jabbour1.   

Abstract

Historically treated with surgery, current practice recommends anal carcinoma to be treated with a combination of chemotherapy and radiation. This review will examine the anatomy, modes of disease spread and recurrence, and evaluate the existing evidence for treatment options for these tumors. An in-depth examination of specific radiation therapy (RT) techniques-such as conventional 3D-conformal RT and intensity-modulated RT-will be discussed along with modern dose constraints. RT field arrangement, patient setup, and recommended gross and clinical target volume (CTV) contours will be considered. Areas in need of further investigation, such as the role in treatment for positron emission tomography (PET) will be explored.

Entities:  

Keywords:  Anal cancer; dose constraints; dosimetric parameters; intensity modulated radiation therapy (IMRT); radiation technique

Year:  2014        PMID： 24982768      PMCID： PMC4074958          DOI： 10.3978/j.issn.2078-6891.2014.026

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  72 in total

1.  An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition.

Authors:  A Taylor; A G Rockall; M E B Powell
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-07-10       Impact factor: 4.126

2.  Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.

Authors:  Jean L Wright; Sujata M Patil; Larissa K F Temple; Bruce D Minsky; Leonard B Saltz; Karyn A Goodman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-29       Impact factor: 7.038

3.  ACR Appropriateness Criteria®-Anal Cancer.

Authors:  Theodore S Hong; Jennifer L Pretz; Joseph M Herman; May Abdel-Wahab; Nilofer Azad; A William Blackstock; Prajnan Das; Karyn A Goodman; Salma K Jabbour; William E Jones; Andre A Konski; Albert C Koong; Miguel Rodriguez-Bigas; William Small; Charles R Thomas; Jennifer Zook; W Warren Suh
Journal:  Gastrointest Cancer Res       Date:  2014-01

4.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.

Authors: 
Journal:  Lancet       Date:  1996-10-19       Impact factor: 79.321

5.  Comparison of the belly board device method and the distended bladder method for reducing irradiated small bowel volumes in preoperative radiotherapy of rectal cancer patients.

Authors:  Tae Hyun Kim; Eui Kyu Chie; Dae Yong Kim; Sung Yong Park; Kwan Ho Cho; Kyung Hae Jung; Young Hoon Kim; Dae Kyung Sohn; Seung-Yong Jeong; Jae-Gahb Park
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

6.  The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer.

Authors:  Kathy L Baglan; Robert C Frazier; Di Yan; Raywin R Huang; Alvaro A Martinez; John M Robertson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038

7.  Carcinoma of the anal canal. A clinical and pathologic study of 188 cases.

Authors:  B M Boman; C G Moertel; M J O'Connell; M Scott; L H Weiland; R W Beart; L L Gunderson; R J Spencer
Journal:  Cancer       Date:  1984-07-01       Impact factor: 6.860

8.  PET-CT fusion in radiation management of patients with anorectal tumors.

Authors:  Cynthia Anderson; Mary Koshy; Charles Staley; Natia Esiashvili; Sharam Ghavidel; Zach Fowler; Tim Fox; Fabio Esteves; Jerome Landry; Karen Godette
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-01       Impact factor: 7.038

9.  Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.

Authors:  S Gillianne DeFoe; Peyman Kabolizadeh; Dwight E Heron; Sushil Beriwal
Journal:  Oncology       Date:  2013-06-01       Impact factor: 2.935

10.  A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy.

Authors:  John C Roeske; Dacian Bonta; Loren K Mell; Anthony E Lujan; Arno J Mundt
Journal:  Radiother Oncol       Date:  2003-11       Impact factor: 6.280
View more
  6 in total

Review 1.  Quality Control of Radiation Delivery for Lower Gastrointestinal Cancers.

Authors:  Supriya Jain; Karyn A Goodman
Journal:  Curr Treat Options Oncol       Date:  2018-09-07

2.  The art and science of radiation therapy for gastrointestinal cancers.

Authors:  Bryan Chang
Journal:  J Gastrointest Oncol       Date:  2014-06

3.  Dosimetric comparison of different radiation techniques (IMRT vs. 3-dimensional) of the "true" (deep) ano-inguinal lymphatic drainage of anal cancer patients.

Authors:  Hendrik Dapper; Markus Oechsner; Christoph Hirche; Stefan Münch; Christina Sauter; Kai Borm; Jan C Peeken; Stephanie E Combs; Daniel Habermehl
Journal:  Radiat Oncol       Date:  2018-11-22       Impact factor: 3.481

4.  Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer.

Authors:  Julia Koeck; Frank Lohr; Daniel Buergy; Karen Büsing; Marcus J Trunk; Frederik Wenz; Sabine Mai
Journal:  Radiat Oncol       Date:  2016-04-04       Impact factor: 3.481

5.  Unforeseen Computed Tomography Resimulation for Initial Radiation Planning: Associated Factors and Clinical Impact.

Authors:  April Metzger; Paul Renz; Shaakir Hasan; Stephen Karlovits; Jason Sohn; Steven Gresswell
Journal:  Adv Radiat Oncol       Date:  2019-06-20

6.  Intravenous contrast media in radiation therapy planning computed tomography scans - Current practice in Ireland.

Authors:  Shane Minogue; Charles Gillham; Maeve Kearney; Laura Mullaney
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2019-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.